Sage Therapeutics filings document a brain-health biopharmaceutical issuer and its public-company transition, including Form 25 removal of its common stock from Nasdaq listing and Form 15 termination or suspension of Exchange Act reporting obligations. The records identify the covered security as common stock and reflect the company’s reduced holder-of-record status at the time of deregistration.
Company 8-K filings also record material events, financial-results releases, capital-structure disclosures, governance matters, and transaction-related disclosures. Earlier operating disclosures covered ZURZUVAE collaboration revenue, pipeline programs such as SAGE-319, clinical and regulatory topics, risk factors, and business updates for the company’s brain-health drug development and commercialization activities.
The Reporting Persons — Madison Avenue International LP, Madison Avenue Partners LP, EMAI Management, LLC, Madison Avenue GP, LLC, Caraway Jackson Investments LLC and Eli Samaha — disclosed beneficial ownership of 6,077,065 shares of Sage Therapeutics common stock, representing approximately 9.7% of the 62,620,694 shares used as the basis for the calculation. The ownership is reported as shared voting and shared dispositive power, with no sole voting or dispositive power claimed.
The statement was filed on Schedule 13G, indicating a passive stake, and includes a certification that the securities were not acquired to change or influence control of the issuer.